Conventional Therapy in Pediatric Hypophosphatemic Rickets: Growth Outcomes and Nephrocalcinosis Risk

Objective

Hypophosphatemic rickets (HR) is characterized by renal phosphate wasting and impaired skeletal mineralization. Although conventional therapy with oral phosphate and active vitamin D analogues remains widely used, its long-term biochemical, auxological, and renal outcomes are variable. This study aimed to evaluate longitudinal biochemical changes, growth patterns, cumulative phosphate exposure, and nephrocalcinosis (NC) development in children with HR receiving conventional therapy. Materials and Methods: This retrospective single-center case series included 20 children with HR followed for at least 1 year. Clinical, biochemical, and auxological parameters were recorded at baseline and annually. Longitudinal analyses were performed in patients with complete 3-year follow-up (n = 10) using the Friedman test, and cumulative phosphate exposure was compared according to NC status.